NCT02883062 — National Cancer Institute (NCI) cancer immunotherapy trial
Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer
Registry record
| Registry ID | NCT02883062 ↗ |
|---|---|
| Lead sponsor | National Cancer Institute (NCI) |
| Collaborators | — |
| Phase | Phase 2 |
| Status | Active Not Recruiting |
| Indication | Invasive Breast Carcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma |
| Enrollment | 67 participants (target) |
| Start date | 2017-08-02 |
| Primary completion | 2019-12-18 |
| Last registry update | 31 Jul 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT02883062), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT02883062?
NCT02883062 (Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer) is registered on ClinicalTrials.gov as Phase 2, sponsored by National Cancer Institute (NCI).
Is NCT02883062 recruiting?
As of the 2026-07-31 registry update, NCT02883062 is listed as "Active Not Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT02883062?
The lead sponsor is National Cancer Institute (NCI).
What condition does NCT02883062 study?
The registered conditions are Invasive Breast Carcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma. Primary completion is listed as 2019-12-18.
Are results available for NCT02883062?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT02883062.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.